|Articles|March 25, 2019
- Drug Topics April 2019
- Volume 163
- Issue 4
Bayer, J&J Pay $775 Million in Xarelto Lawsuits
Author(s)Drew Boxler
More than 25,000 lawsuits cite uncontrollable and irreversible bleeding and death.
Advertisement
Bayer AG and Johnson & Johnson have agreed to jointly settle $775 million in lawsuits over their Xarelto (rivaroxaban) blood thinner.
More than 25,000 plaintiffs have accused the drug makers of failing to warn of the bleeding risks associated with Xarelto and believe that their injuries could have been prevented with adequate information.
Trending:
Injuries cited in the cases include the development of uncontrollable and irreversible bleeding, which has led to severe injuries and deaths. Anticoagulants as a category were linked with about 3,000 deaths in 2016, according to the Institute for Safe Medication Practices.
Xarelto has proven to be Bayer’s best-selling drug, earning $4.07 billion (€3.6 billion). J&J reported $2.47 billion earned from the drug.
Articles in this issue
about 7 years ago
Profiles of Four Travel Health Clinicsabout 7 years ago
Prucalopride Approved for Idiopathic Constipationabout 7 years ago
Clinical Pharmacists Are Integral Team Members in PCMHsabout 7 years ago
Four Strategies for Reacting to Rude Customersabout 7 years ago
Resources for Getting Started with Telepharmacyabout 7 years ago
Harnessing Technology to Enhance Diabetes Adherenceabout 7 years ago
Telepharmacy's New Frontiers Expand Business OpportunitiesAdvertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
McKesson Partners with Pharmacies to Grow, Navigate Challenges
2
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
3
US Controlled Substance Market Expected to Grow $21 Billion by 2035
4
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
5